Cassava Sciences Stock Today
| SAVA Stock | USD 2.72 0.07 2.51% |
PerformanceOK
| Odds Of DistressAverage
|
Cassava Sciences is trading at 2.72 as of the 19th of March 2025, a 2.51 percent decrease since the beginning of the trading day. The stock's open price was 2.79. Cassava Sciences has 54 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of July 2000 | Category Healthcare | Classification Health Care |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Cassava Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 48.31 M outstanding shares of which 15.94 M shares are at this time shorted by private and institutional investors with about 10.16 trading days to cover. More on Cassava Sciences
Moving against Cassava Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cassava Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Remi Barbier | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCassava Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cassava Sciences' financial leverage. It provides some insight into what part of Cassava Sciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cassava Sciences (SAVA) is traded on NASDAQ Exchange in USA. It is located in 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731 and employs 30 people. Cassava Sciences is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 134.78 M. Cassava Sciences conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 48.31 M outstanding shares of which 15.94 M shares are at this time shorted by private and institutional investors with about 10.16 trading days to cover.
Cassava Sciences currently holds about 197.23 M in cash with (116.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cassava Sciences Probability Of Bankruptcy
Ownership AllocationCassava Sciences holds a total of 48.31 Million outstanding shares. 30% of Cassava Sciences outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cassava Ownership Details
Cassava Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jane Street Group Llc | 2024-12-31 | 400.2 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 319.7 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 280.4 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 278.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 266.2 K | |
| Myda Advisors Llc | 2024-12-31 | 169.5 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 165.5 K | |
| Lmr Partners Llp | 2024-12-31 | 161.5 K | |
| Gallacher Capital Management Llc | 2024-12-31 | 152.9 K | |
| Blackrock Inc | 2024-12-31 | 3.7 M | |
| Vanguard Group Inc | 2024-12-31 | 2.5 M |
Cassava Sciences Historical Income Statement
Cassava Stock Against Markets
Cassava Sciences Corporate Management
| Christopher JD | Company VP | Profile | |
| James MD | Chief Officer | Profile | |
| Michael Zamloot | Senior Operations | Profile | |
| Jaren Landen | Chief Officer | Profile | |
| Michael PharmD | Senior Affairs | Profile | |
| Lindsay Burns | Senior Neuroscience | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Cassava Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Cassava Stock refer to our How to Trade Cassava Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cassava Sciences. If investors know Cassava will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cassava Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cassava Sciences is measured differently than its book value, which is the value of Cassava that is recorded on the company's balance sheet. Investors also form their own opinion of Cassava Sciences' value that differs from its market value or its book value, called intrinsic value, which is Cassava Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cassava Sciences' market value can be influenced by many factors that don't directly affect Cassava Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cassava Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cassava Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cassava Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.